RecruitingNon-small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNSCLC

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

You may qualify if…

✓ Histologically documented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation
✓ Measurable disease by RECIST v1.1
✓ Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

You may not qualify if…

✕ Patients with malignancy within the last 2 years as specified in the protocol
✕ Patients with untreated or unstable brain metastases
✕ Patients with known hypersensitivity to BBO-8520 or its excipients
✕ For Cohorts 1b and 2b:
✕ Patients with a known hypersensitivity to pembrolizumab or its excipients
✕ Patients with active autoimmune disease of history of autoimmune disease that might recur
✕ Patients with a history of interstitial lung disease/pneumonitis that required steroids, or current interstitial lung disease/pneumonitis
✕ Other inclusion/exclusion criteria may apply